Fat Science

Have you ever wondered if you should get liposuction when you need skin removal surgery after major weight loss?In this mailbag episode, Dr. Cooper, Mark, and Andrea tackle questions from listeners around the world, from Germany to Alabama to Chicago. They discuss why restricting calories while on GLP-1 medications can actually work against you, address the reality of finding metabolic-informed doctors internationally, and explain the science behind fat cell removal during skin surgeries. Plus, they share details about the newly approved oral GLP-1 medication orforglipron (Foundayo) and why vegetables, fats and starches matter even when you're protein-focused.KEY TAKEAWAYSRestricting calories on GLP-1 medications can lower your metabolic rate and weaken your body's natural GLP-1 productionLiposuction during skin removal surgery may disrupt leptin signaling, though males may be less affected than females due to naturally lower leptin levelsFinding metabolic-informed doctors globally remains challenging, but obesity medicine certification and Canadian and European obesity organizations may offer better resourcesThe oral GLP-1 medication orforglipron will likely be less expensive but also less effective than dual-agonist medications like tirzepatideMechanical eating without calorie counting often produces better long-term results than restrictive approachesVegetables provide essential micronutrients and support healthy microbiome function that protein alone cannot replaceMajor weight loss surgery like tummy tucks is serious surgery that requires careful consideration and qualified surgeonsNOTE: This episode was recorded before Foundayo (orforglipron) was released on the market. The price is the same as the Wegovy pill. Listen to our episode - “New Obesity Drugs” for more information https://podcasts.apple.com/us/podcast/fat-science/id1715377331?i=1000762362056NOTABLE QUOTE"If only they didn't fall into that diet cycle, some of them, their weight would be a hundred pounds less. Yes, it might be still elevated, but a large chunk of that weight was caused by the diet cycle itself." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.Key TakeawaysFoundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.Notable Quote"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting a GLP-1 prescription from someone who's never examined you?Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.KEY TAKEAWAYSGLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribingDirect-to-consumer microdosing platforms lack FDA approval and proper medical oversightThe erosion of trust in healthcare has created opportunities for unregulated treatmentsComprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plansTechnology should enhance medical care, not replace proper physician evaluationNOTABLE QUOTE"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily CooperGUEST BIODr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.GLOSSARYGLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and ZepboundMicrodosing: Taking smaller amounts of medication than officially prescribed or approvedDirect-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platformsHRV: Heart rate variability, a measurement of the variation in time between heartbeatsPre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetesLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Ever wonder why fasting worked at first — then stopped? Or why you lost 80 pounds only to gain back 100?In this mailbag episode, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the most misunderstood topics in metabolic health. From the harsh reality of fasting culture to the surprising metabolic challenges faced by normal-weight individuals, this conversation validates what you've been experiencing and explains the science behind it. You'll also hear why GLP-1 medications aren't just weight loss drugs, why your body might be fighting you even when you're doing everything right, and what happens when your job — like shift work or firefighting — disrupts your metabolism for years.KEY TAKEAWAYSYou can have metabolic dysfunction at a normal weight with what appear to be normal labs, for example, when insulin is over suppressed from chronic under-fueling or overexercisingFasting triggers the same biological adaptation as any restrictive diet and typically results in weight regain that's 22 percent higher than starting weightFood noise is biological, not psychological, and stems from an imbalance of hormones and neurotransmitters signaling nutritional insecurityGLP-1 medications may improve immune function because metabolic health and immunity are deeply connectedShift work and chronic sleep disruption can cause real metabolic damage by weakening leptin signals, increasing insulin resistance, and amplifying hunger hormonesNOTABLE QUOTE"You can't trick your body. You have to have that foundational fueling in there." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Think squashing your post-meal glucose spike is the healthy thing to do? What if that flat line on your CGM is actually telling your brain you didn't eat — and slowing your metabolism as a result?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor open the mailbag to tackle listener questions from around the world — Australia, New Zealand, and across the U.S. They dig into hormone replacement therapy and metabolism, why your GLP-1 medication might be causing hair loss, what a normal blood sugar response actually looks like, and how lipedema differs from obesity. Dr. Cooper also revisits metabolic syndrome and why it's not outdated — just underutilized.Key TakeawaysHormone replacement therapy isn't a reliable tool for improving metabolism — it's better suited for symptom relief and bone health in specific situations.Progesterone, which must accompany estrogen if you still have your uterus, can actually disrupt metabolism in some women — acting almost like a steroid.A flat glucose line after eating isn't the goal — your brain needs to see glucose go up to register that you've been nourished and keep your metabolism running.Hair loss on GLP-1 medications is more likely tied to nutrient deficiencies (especially iron and protein) than the drugs themselves.Lipedema is a disease of the fat tissue itself — separate from obesity — and tirzepatide may help reduce the inflammatory symptoms even though it won't eliminate the fat deposits.Notable Quote"If your glucose is flat line, your brain's not very convinced that you ate much — and then you're not getting the metabolic benefit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Wegovy Pill: Who's It For?The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.Key TakeawaysThe Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as RybelsusSemaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular riskThe pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectivenessThe pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum doseNovo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest doseEli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritualNotable Quote"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions from California, the UK, France, Washington, Wyoming, and beyond. The team breaks down why Dr. Cooper does not recommend calorie tracking (and when limited tracking can make sense), how to build confidence in eating without data, and why “mechanical eating” sometimes needs medical customization—especially for people with slow gut transit or gastroparesis-like symptoms. They also dig into bile acid malabsorption after gallbladder removal, when metformin side effects deserve a second look, what we currently know about COVID-19’s potential impact on metabolic health, and why metformin and GLP-1 medications can be complementary—particularly in PCOS.Key Takeaways• Long-term calorie tracking can override physiologic cues and reinforce diet mentality.• Short-term, targeted tracking may be useful when guided by a clinician (e.g., nutrient deficiencies ).• Obesity and abnormal appetite are both manifestations of metabolic dysfunction—not simple cause and effect.• Mechanical eating is a framework, not a rigid rule—timing and food choices may need medical tailoring.• Post-gallbladder diarrhea may reflect bile acid malabsorption and can be treatable.• Metformin and GLP-1s often complement each other because they target different metabolic states (fasting vs fed).Dr. Cooper’s Actionable Tips• Stop daily calorie counting—focus on consistent patterns and metabolic nourishment.• Use mechanical eating basics: eat every few hours, include all food groups, and reduce chemical additives when possible.• If you’re transitioning away from tracking, consider a dietitian skilled in diet-mentality recovery.• If frequent eating worsens sleep or bloating, work with a medical dietitian to adjust intervals and food types (especially with slow GI transit).• If chronic diarrhea appears (especially after gallbladder removal), ask your clinician about bile acid malabsorption and treatment options.• Use labs to guide therapy: fasting insulin can signal metformin benefit; post-meal patterns can point toward GLP-1 needs.Notable Quote“Once you start using tracking to stay in a calorie range or a carbohydrate range, you’re putting your brain in front of your physiologic intuition—your body is sending you important cues all the time.”—Dr. Emily CooperLinks & ResourcesThe Metabolic Links to PCOS, Release Date 2/24/25The COVID Connection to Diabetes & Metabolic Health, Release Date 12/16/24Podcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.com*Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down two GLP-1 studies that challenge a major media myth: GLP-1 medications don’t drive weight loss just because people eat less. Instead, drugs like tirzepatide and semaglutide create direct metabolic shifts—including increased fat oxidation and improved fuel partitioning—regardless of appetite.The team also explores mechanical eating, the psychological impact of “diet food,” and Andrea’s 13-year metabolic recovery journey.Key Questions AnsweredIf both groups are dieting, why does the tirzepatide group lose more weight?What is metabolic adaptation, and why does dieting slow metabolism so sharply?How do GLP-1s directly increase fat oxidation?What is mechanical eating, and why do GLP-1 users need it?Why does ad-lib eating produce different metabolic responses than calorie restriction?Can mindset alone change hunger hormones? (Yes—the milkshake study.)Why do diet foods and diet sodas fail to improve metabolic health?Why is response to GLP-1s so different from person to person?Key TakeawaysGLP-1s are metabolic drugs—not appetite suppressants.Their power comes from hormonal effects on fat burning, not reduced food intake.Calorie restriction still slows metabolism.Even on GLP-1s, dieting triggers significant metabolic slowdown.Ad-lib eating outperforms dieting in the research.Semaglutide users who ate freely did not show the extra metabolic slowdown seen in dieters.Mechanical eating is the most durable long-term approach.Regular meals and snacks protect lean mass and prevent famine signaling.Mindset shapes hormones.Believing a food is “diet” vs. “indulgent” alters ghrelin and satisfaction.Track body composition—not just the scale.DEXA scans show whether you’re losing fat, muscle, or bone.Dr. Cooper’s Actionable TipsDon’t diet on GLP-1s. Focus on fueling, not restriction.Use mechanical eating: predictable meals and snacks, no long gaps.Prioritize satisfaction: diet foods often backfire hormonally.Follow your real-world data: long-term changes matter more than short-term scale shifts.Ask about body composition testing if possible.Notable Quote:“What that study proved is that doing the calorie restriction is causing the metabolic slowing… and that’s why it’s so confusing to me that we keep advising people to restrict calories when they’re trying to improve their metabolic function.” —Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.comDr. Cooper Email: dr.c@fatsciencepodcast.comFat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational only, and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with pediatric eating disorder specialist Dr. Julie O’Toole (Kartini Clinic) and pediatric obesity expert Dr. Evan Nadler about what childhood obesity really is: a biologic, metabolic disease—not a willpower problem and not a failure of parenting.They explore how excess weight, constant hunger, and disordered eating in kids are often signs of underlying metabolic dysfunction and genetics—and why the old “eat less, move more” advice can do real harm, especially when children are shamed or restricted in the name of “health.”Key Questions AnsweredWhy is childhood obesity a metabolic disease, not a behavior problem?How are obesity and eating disorders deeply connected instead of opposite extremes?What role do GLP-1 medications play in children—and how do we protect against under-fueling?When should parents suspect genetic drivers like hyperphagia or MC4 mutations?How can medical treatment for obesity actually reduce disordered eating behaviors?When does excess weight become a medical issue requiring metabolic evaluation—not another diet?Key TakeawaysWeight is a symptom. Childhood obesity is often a sign of metabolic dysfunction, not overeating.Obesity & eating disorders overlap. Restriction can trigger disordered eating; disordered eating can worsen obesity.“Eat less, move more” harms. Shame-based approaches delay treatment and increase risk of eating disorders.GLP-1s work metabolically, not just through appetite suppression. Kids still need consistent fueling.Genetics matter. Single-gene differences can drive severe childhood hunger & rapid weight gain.Not treating is harm. Avoiding obesity care violates first, do no harm.Dr. Cooper’s Actionable TipsIf your child is gaining weight or constantly hungry, request metabolic labs (insulin, glucose, lipids, liver, hormones).If the doctor only says “eat less, move more,” ask: “How are we evaluating metabolism and genetics?”On GLP-1s? Monitor for under-fueling (skipped meals, low energy, food anxiety) and intervene promptly.Notable Quote“Not treating childhood obesity is doing harm. It’s a disease, not a lifestyle choice.” — Dr. Evan NadlerLinks & ResourcesPodcast Home: Fat Science WebsiteEpisodes & Show Archive: Cooper Center Podcast PageEducation & Metabolic Resources: coopermetabolic.com/resourcesSubmit a Show Question: questions@fatsciencepodcast.comEmail Dr. Cooper Directly: dr.c@fatsciencepodcast.comConnect with Our GuestsDr. Evan P. Nadler, MD, MBA – Founder, ProCare Consultants & ProCare TeleHealthWebsite: obesityexplained.comYouTube Channel: Obesity ExplainedDr. Julie K. O’Toole, M.D., M.P.H. – Chief Medical Officer & Founder, Kartini ClinicWebsite: kartiniclinic.comBooks: amazon.com/author/julieotoole*Fat Science breaks diet myths and advances the science of real metabolic health. No diets. No agendas. Just science that makes you feel better. This episode is informational only and not medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor unpack the biggest GLP-1 headlines from around the world—from the World Health Organization’s first-ever GLP-1 obesity guidelines to access battles, brain research, and the coming wave of generics and new meds.Dr. Cooper explains what the WHO’s move really means for patients, why long-term treatment matters, and how policy decisions in places like California and India could reshape who actually benefits from these breakthroughs. This isn’t hype—it’s metabolic medicine, health-system reality, and grounded hope.Key Questions AnsweredWhy is the WHO’s new guidance on GLP-1s for obesity such a historic turning point?What does it mean to treat obesity as a chronic, relapsing disease—not a willpower problem?Why do GLP-1s usually need to be taken long term, and how is that similar to blood pressure or cholesterol meds?How should GLP-1s be paired with metabolic care—fueling, sleep, movement, and real clinical oversight?What did the “stone cold negative” Alzheimer’s trials show—and why are addiction trials still promising?How could India’s launch of Ozempic and future generics impact global pricing and access?What new GLP-1 and metabolic drugs are on the horizon (like orforglipron, higher-dose oral semaglutide, and GLP-1/amylin combos)?Key TakeawaysWHO is catching up to the science. Obesity is affirmed as a chronic, relapsing disease that deserves pharmacologic treatment—not “eat less, move more” lectures or moral judgment.Long-term meds are the rule, not the exception. Stopping GLP-1s usually leads to weight and risk factors returning, just like stopping blood-pressure meds. That’s physiology, not failure.Behavior ≠ blame. WHO calls for pairing GLP-1s with “behavioral” care—but Dr. Cooper reframes this around fueling, sleep, and supported habits, not deprivation or diet culture.Access is the battleground. Even as WHO elevates GLP-1s, programs like California’s Medi-Cal are cutting coverage for obesity, a move Dr. Cooper calls penny-wise and pound-foolish given the downstream costs of diabetes and cardiovascular disease.Brain outcomes are nuanced. Large oral semaglutide trials failed to slow Alzheimer’s, but GLP-1s (and other obesity meds) still show promise for addiction by modulating reward pathways and the “internal drug factory” (POMC).Global markets are shifting. India’s huge population, looming Ozempic patent expirations, and emerging generics could eventually drive prices down—especially as more manufacturers compete.New meds may expand options. Orforglipron (a small-molecule oral GLP-1), higher-dose oral semaglutide, and a weekly GLP-1/amylin combo could bring more flexible, powerful, and potentially more affordable tools.Dr. Cooper’s Actionable TipsThink of obesity treatment like any chronic disease: long-term, medical, and individualized—not a short-term “diet.”If you’re using a GLP-1, pair it with real metabolic care: consistent fueling (not under-eating), good sleep, and appropriately fueled exercise.Be cautious with “cheap” or unsanctioned online GLP-1 options—especially if you’re being squeezed out of coverage. Safety and oversight matter.Remember there are other evidence-based obesity meds beyond GLP-1s; if you can’t tolerate or access one class, ask your clinician about alternatives.Notable Quote“Your metabolism is a lifelong issue. It’s not a headache.”— Andrea TaylorLinks & ResourcesPodcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/ Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/ Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/ Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.com*Fat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with Maria from Buffalo, a longtime listener who shares her lifelong journey with obesity, psoriatic arthritis, and binge eating—and how finally understanding the science of metabolism gave her hope. Maria describes early childhood weight gain, joint damage, and years of restrictive dieting and food shame, then explains how GLP‑1 therapy (Zepbound) plus mechanical eating helped her lose about 50 pounds while eating more food, more often, and with more joy. Dr. Cooper breaks down the underlying biology—leptin, weight set point, the melanocortin pathway, and the impact of pain, sleep, and chronic inflammation on hunger hormones—and reframes obesity as a symptom of deeper metabolic problems, not a character flaw. This episode doubles as a practical, emotionally honest guide for patients trying to navigate a traditional health‑care system without a dedicated metabolic specialist.Key Questions AnsweredHow can rapid childhood weight gain, autoimmune disease, and early joint damage signal serious metabolic dysfunction rather than “too much food” or “not enough exercise”?What is leptin, what does “too low for your size” mean, and how does that affect hunger, weight set point, and weight loss?What is monogenic obesity testing, who might qualify for free genetic screening, and how can results inform (but not necessarily change) treatment?How do GLP‑1 medications like Zepbound work with mechanical eating so someone can lose weight while eating more regularly and with more variety?Which labs (fasting glucose, insulin, leptin, etc.) help uncover hidden metabolic issues, and when is a mixed‑meal test more useful than a simple fasting snapshot?When should brain‑active medications (such as bupropion/naltrexone combinations) be considered, and what trade‑offs and side effects matter?How can patients respectfully push for tests, challenge old “eat less, move more” advice, and set boundaries around weigh‑ins and stigmatizing language?Key TakeawaysIt’s not your fault: Rapid childhood weight gain and early‑onset obesity often reflect serious metabolic biology, including rare gene variants, growth phases, and hormone signaling—not gluttony or laziness.Obesity is a symptom: Excess weight is better understood as a side effect of underlying metabolic fires (leptin issues, insulin resistance, brain signaling problems) that need proper diagnosis and treatment.Leptin really matters: Low leptin for your size can act as a biological brake on weight loss, and chronic dieting, under‑fueling, over‑exercise, and some high‑dose supplements can suppress it further.GLP‑1s plus mechanical eating: Medications like Zepbound can quiet food noise and support weight loss, but scheduled, balanced eating is essential to avoid under‑fueling, protect muscle, and support hormones.Pain and sleep are metabolic: Chronic pain and poor sleep increase hunger hormones like ghrelin and disrupt repair processes, worsening metabolic dysfunction unless directly addressed.Script your visits: Bring a printed list of diagnoses, medications, and questions; use patient portals to request specific tests; and practice simple boundary phrases around weighing and diet talk.Notable Quote“This isn’t all just caused by diets and things like that. There was an original metabolic problem. It was amplified because of the food restriction and the psychology around it, but you are a product of cumulative insults to your system—not a moral failure.” — Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it’s metabolic medicine, mythbusting, and science-backed encouragement for your journey.Key Questions AnsweredWhat is the “selfish brain” and how does it really impact blood sugar and diabetes risk?Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you’re using them?If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper’s individualized care—and can you taper off meds and maintain results?What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?Key TakeawaysMetabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.Dr. Cooper’s Actionable TipsAlways dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.If you’re prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don’t risk unregulated online compounds. Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.Stay consistent and compassionate—focus on small improvements over extremes and absolutes.Notable Quote“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramGeneric medication access: Mark Cuban Cost Plus DrugsZepbound direct: Lilly DirectAdditional info: Novocare for WegovyFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.